The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, MD Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, Volume 1.1, 44-46. Doi : 10.1089/can.2015.29003.ebr Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held [...]
Lire la suiteCannabis Domestication, Breeding History, Present-day Genetic Diversity, and Future Prospects Robert C. Clarke and Mark D. Merlin CRITICAL REVIEWS IN PLANT SCIENCES, 2016, VOL. 35, NOS. 5–6, 293–327 Doi : 10.1080/07352689.2016.1267498 ABSTRACT Humans and the Cannabis plant share an intimate history spanning millennia. Humans spread Cannabis from its Eurasian homelands throughout much of the world, and, in concert with local climatic and human cultural parameters, created traditional landrace varieties (cultivars resulting from a combination of natural and farmer selection) with few apparent signs of domestication. Cannabis breeders combined populations from widely divergent geographical regions and gene pools to develop economically valuable fiber, seed, and drug cultivars, [...]
Lire la suiteMedical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]
Lire la suiteData Supporting Cannabis for Childhood Epilepsy Remain Scarce Will Pass Medscape.com, September 13, 2021 https://www.medscape.com/viewarticle/958616 Cannabis-based medicinal products (CBMPs) have shown early promise for refractory childhood epilepsy, but positive media attention, as well as pressure from politicians and marijuana advocacy groups, should not supplant clinical trials and acceptable standards of evidence, according to two leading experts. In a recent invited review article, Martin Kirkpatrick, MD, of the University of Dundee (Scotland), and Finbar O'Callaghan, MD, PhD, of University College London suggested that childhood epilepsy may be easy terrain for commercial interests to break ground, and from there, build their presence. "Children with epilepsy are at risk of being [...]
Lire la suiteTerpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors David B. Finlay, Kathleen J. Sircombe, Mhairi Nimick, Callum Jones and Michelle Glass Frontiers in Pharmacology, 2020, Volume 11, Article 359, 1-9. doi : 10.3389/fphar.2020.00359 The entourage effect was a proposed explanation for biological observations that endocannabinoid ligand activities can be modified by other lipids released from cells at the same time. An increasing volume of anecdotal reports and interest in the plant have provoked research into the activity of minor chemical constituents of the plant—including volatile terpenoids such as myrcene, a- and b- pinene, b-caryophyllene, and limonene. However, to [...]
Lire la suiteCannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis Mohamed M. Radwan, Suman Chandra, Shahbaz Gul and Mahmoud A. ElSohly Molecules, 2021, 26, 2774. Doi : 10.3390/molecules26092774 Abstract : Cannabis sativa is one of the oldest medicinal plants in the world. It was introduced into western medicine during the early 19th century. It contains a complex mixture of secondary metabolites, including cannabinoids and non-cannabinoid-type constituents. More than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids. Cannabinoids are C21 terpeno phenolic compounds specific to Cannabis. The non-cannabinoid constituents include: non-cannabinoid phenols, flavonoids, terpenes, alkaloids and others. This review discusses [...]
Lire la suiteAbsence of Entourage : Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors Marina Santiago, Shivani C. Arnold, Iain S., McGregor and Mark Connor Cannabis and Cannabinoid Research, 2019, Vol. 4, No. 3 doi : 10.1089/can.2019.0016 Abstract Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling. Therefore, we examined six common terpenoids alone, [...]
Lire la suiteCannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment Anna Stasiłowicz, Anna Tomala, Irma Podolak and Judyta Cielecka-Piontek International Journal of Molecular Sciences, 2021, 22, 778. Doi : 10.3390/ijms22020778 Abstract : Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results [...]
Lire la suiteCannabis : From Cultivar to Chemovar II—A Metabolomics. Approach to Cannabis Classification Arno Hazekamp, Katerina Tejkalova, and Stelios Papadimitriou Cannabis and Cannabinoid Research, 2016, Volume 1, (1) Doi : 10.1089/can.2016.0017 Abstract Introduction : There is a large disparity between the ‘‘cultural’’ language used by patients using cannabis for selfmedication and the ‘‘chemical’’ language applied by scientists to get a deeper understanding of cannabis effects in laboratory and clinical studies. The distinction between Sativa and Indica types of cannabis, and the different biological effects associated with them, is a major example of this. Despite the widespread use of cannabis by selfmedicating patients, scientific studies are yet [...]
Lire la suiteL’Italie classe les fleurs de chanvre parmi les plantes médicinales Aurélien BERNARD NEWSWEED.fr, 8 octobre 2020 https://www.newsweed.fr/italie-classe-fleurs-chanvre-plantes-medicinales/ Un arrêté du Ministère italien des Politiques agricoles, alimentaires et forestières publié en août a classé la fleur de chanvre à usage extractif (« canapa infiorescenza a uso estrattivo« ) parmi les plantes médicinales. Quelles conséquences pour le marché italien du chanvre ? Selon Giacomo Bulleri, avocat au conseil d’administration de l’association italienne de chanvre Federcanapa, les conséquences pour le secteur chanvrier italien sont importantes. D’une part, l’inclusion de la fleur de chanvre sur la liste des plantes médicinales suggère que la plante est sur le point d’être reconnue comme un produit agricole. D’autre [...]
Lire la suite